ArticleCancer immunology, immunotherapy : CII2018

Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein.

Zeyan Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.